Q-omics provides the consensus-scored SUCLG2P2 profile across patient tissues and cancer cell-line models. SUCLG2P2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUCLG2P2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SUCLG2P2 RNA expression shows 18,677 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where SUCLG2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUCLG2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUCLG2P2 survival associations across molecular data types. SUCLG2P2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUCLG2P2 RNA expression–survival associations across cancer types. High SUCLG2P2 expression shows unfavorable associations in LUAD, but favorable associations in KIRC, COAD, SKCM, READ and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUCLG2P2 RNA expression.
This table summarizes SUCLG2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SUCLG2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUCLG2P2 shows lower tumor expression in KIRC, KIRP, LUSC, HNSC, READ and CHOL. The KIRC box plot shows higher SUCLG2P2 RNA expression in normal versus tumor tissue (log2 FC = −0.478, t-test p < 0.001).
This table shows molecular features associated with SUCLG2P2 in patient tissues and cancer cell lines. In patient samples, SUCLG2P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
